AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,975,812 | -34.2% | 162,485 | -32.0% | 0.00% | -20.0% |
| Q2 2023 | $3,002,999 | +0.9% | 239,091 | -10.9% | 0.01% | -16.7% |
| Q1 2023 | $2,977,314 | -22.4% | 268,467 | -14.5% | 0.01% | -33.3% |
| Q4 2022 | $3,834,956 | -9.0% | 314,081 | -22.2% | 0.01% | 0.0% |
| Q3 2022 | $4,212,000 | -15.3% | 403,449 | -12.9% | 0.01% | -18.2% |
| Q2 2022 | $4,972,000 | +19.8% | 463,131 | +5.7% | 0.01% | +37.5% |
| Q1 2022 | $4,151,000 | -19.4% | 438,340 | -1.6% | 0.01% | -20.0% |
| Q4 2021 | $5,147,000 | +16.9% | 445,682 | -3.3% | 0.01% | +11.1% |
| Q3 2021 | $4,402,000 | -3.1% | 460,993 | -2.1% | 0.01% | -10.0% |
| Q2 2021 | $4,541,000 | -12.7% | 471,085 | +5.2% | 0.01% | -23.1% |
| Q1 2021 | $5,202,000 | -64.3% | 447,933 | -29.0% | 0.01% | -65.8% |
| Q4 2020 | $14,563,000 | +63.6% | 630,601 | +0.1% | 0.04% | +46.2% |
| Q3 2020 | $8,899,000 | +0.1% | 630,097 | +6.9% | 0.03% | -7.1% |
| Q2 2020 | $8,889,000 | +60.0% | 589,480 | -2.0% | 0.03% | +40.0% |
| Q1 2020 | $5,556,000 | -3.9% | 601,314 | +1.3% | 0.02% | +17.6% |
| Q4 2019 | $5,782,000 | +114.1% | 593,612 | +76.3% | 0.02% | +142.9% |
| Q3 2019 | $2,701,000 | -38.5% | 336,722 | -4.2% | 0.01% | -50.0% |
| Q2 2019 | $4,389,000 | -2.6% | 351,662 | +6.2% | 0.01% | -6.7% |
| Q1 2019 | $4,504,000 | +32.5% | 331,151 | +17.8% | 0.02% | +25.0% |
| Q4 2018 | $3,399,000 | 0.0% | 281,146 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $3,399,000 | +536.5% | 281,146 | +723.5% | 0.01% | +500.0% |
| Q2 2018 | $534,000 | +17700.0% | 34,142 | +14616.4% | 0.00% | – |
| Q1 2018 | $3,000 | 0.0% | 232 | 0.0% | 0.00% | – |
| Q4 2017 | $3,000 | 0.0% | 232 | +5.5% | 0.00% | – |
| Q3 2017 | $3,000 | +50.0% | 220 | 0.0% | 0.00% | – |
| Q2 2017 | $2,000 | -99.7% | 220 | -99.5% | 0.00% | -100.0% |
| Q3 2015 | $669,000 | – | 47,832 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |